Last reviewed · How we verify
Naltrexone implant, 14.4 grams — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Naltrexone implant, 14.4 grams (Naltrexone implant, 14.4 grams) — Akyso Therapeutics, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Naltrexone implant, 14.4 grams TARGET | Naltrexone implant, 14.4 grams | Akyso Therapeutics, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Naltrexone implant, 14.4 grams CI watch — RSS
- Naltrexone implant, 14.4 grams CI watch — Atom
- Naltrexone implant, 14.4 grams CI watch — JSON
- Naltrexone implant, 14.4 grams alone — RSS
Cite this brief
Drug Landscape (2026). Naltrexone implant, 14.4 grams — Competitive Intelligence Brief. https://druglandscape.com/ci/naltrexone-implant-14-4-grams. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab